Fusion Pharmaceuticals Inc. Long-Term Debt, Maturity, Year Four
Fusion Pharmaceuticals Inc. had Long-Term Debt, Maturity, Year Four of $6.09 million as of 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour · last filed 2024-03-20
- 2023-12-31: Long-Term Debt, Maturity, Year Four $6.09M.
- 2023-09-30: Long-Term Debt, Maturity, Year Four $6.09M.
- 2023-06-30: Long-Term Debt, Maturity, Year Four $6.09M.
- 2023-03-31: Long-Term Debt, Maturity, Year Four $6.09M.
| Period end | Long-Term Debt, Maturity, Year Four |
|---|---|
| 2023-12-31 | $6.09M 10-K · filed 2024-03-20 |
| 2023-09-30 | $6.09M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $6.09M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $6.09M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.26M 10-K · filed 2023-03-16 |
| 2022-09-30 | $18.26M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.22M 10-Q · filed 2022-08-09 |